News from the Beijing News On May 10, Yiling Pharmaceutical announced that it has recently received a drug registration certificate approved and issued by the Nigerian State Food and Drug Administration, approving the company’s drug Lianhua Qingwen Capsules in Nigeria. Registered with the State Food and Drug Administration.
Lianhua Qingwen products are the leading products of Yiling Pharmaceutical, National Essential Medicines List and National Medical Insurance List (Class A) varieties, mainly used for colds , Treatment of influenza-related diseases. Lianhua Qingwen products have been included in the diagnosis and treatment plan of cold and flu-related diseases by the National Health Commission and the State Administration of Traditional Chinese Medicine for many times. Lianhua Qingwen capsules/granules are listed as the recommended drugs in the “New Coronavirus Pneumonia Diagnosis and Treatment Program” (trial version 4/5/6/7/8/9) jointly issued by the National Health Commission and the State Administration of Traditional Chinese Medicine. On April 12, 2020, the State Drug Administration approved Lianhua Qingwen capsules/granules to add a new indication of “new coronavirus pneumonia mild and common” on the basis of the original approved indications. In 2021, Yiling Pharmaceutical’s Lianhua Qingwen products achieved operating income of 4.060 billion yuan, accounting for 40.15% of the company’s total operating income.
Yiling Pharmaceutical said that Lianhua Qingwen Capsules obtained the Nigeria drug registration certificate this time, indicating that the company has the ability to use herbal and natural medicines in the Nigerian market. The qualification to sell the product will have a positive impact on the company’s expansion into overseas markets.
Up to now, Lianhua Qingwen Capsules have been sold in Hong Kong, Macau and Indonesia, Thailand, Singapore, Philippines, Mongolia and other countries respectively. “Proprietary Chinese Medicine”, “Medicine”, “Botanical Medicine”, “Food Supplement”, “Modern Herbal Medicine”, “Natural Medicine” and other identities have been registered and approved for marketing. At present, overseas sales revenue accounts for a relatively low proportion of the company’s total operating revenue.
Proofreading Zhang Yanjun